These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. Merello M; Lees AJ J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397 [TBL] [Abstract][Full Text] [Related]
31. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272 [TBL] [Abstract][Full Text] [Related]
32. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide. Kurth MC Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854 [TBL] [Abstract][Full Text] [Related]
33. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. Rascol O; Sabatini U; Chollet F; Fabre N; Senard JM; Montastruc JL; Celsis P; Marc-Vergnes JP; Rascol A J Neurol Neurosurg Psychiatry; 1994 May; 57(5):567-71. PubMed ID: 8201325 [TBL] [Abstract][Full Text] [Related]
34. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. Tarsy D; Parkes JD; Marsden CD J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689 [TBL] [Abstract][Full Text] [Related]
35. A review of current and novel levodopa formulations for the treatment of Parkinson's disease. Jimenez-Shahed J Ther Deliv; 2016; 7(3):179-91. PubMed ID: 26893250 [TBL] [Abstract][Full Text] [Related]
36. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
37. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Factor SA; Weiner WJ Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289 [TBL] [Abstract][Full Text] [Related]
38. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754 [TBL] [Abstract][Full Text] [Related]
39. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Kostic V; Przedborski S; Flaster E; Sternic N Neurology; 1991 Feb; 41(2 ( Pt 1)):202-5. PubMed ID: 1992362 [TBL] [Abstract][Full Text] [Related]
40. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. LeWitt PA Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]